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Figure 1. The linearity was analyzed by serially diluting (1:2, 1:4, 1:8, and
1:10)the mixed QC samples (MQC) and the unspiked pooled samples (P). The
observed concentration was plotted against the reciprocal of the dilution.
loss in the stability of the CTX II epitope out to 4 freeze/thaw
cycles. Differences in biological activity were identiﬁed when ex-
amining samples from 3 normal rested horses (111.40 ± 33.3
pg/ml), the same horses after 5 months race-training (158.18 ±
111 pg/ml), and those with naturally-occurring OC injuries (38.96
± 12.91 pg/ml) (Figure 2).
Figure 2. Differences in biological activity identiﬁed between samples from 3
horses before (Rested) and after 5 months race-training (Exercised) as well as
3 horses with OA. Signiﬁcant differences between groups are represented as
*P<0.05 using a Kruskal-Wallis test.
Conclusions: The Serum Pre-Clinical Cartilaps® ELISA is a
reproducible and valid assay for use with equine serum.
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A. Pilichou, N. Efstathopoulos, S. Pneumaticos, G. Papachristou
Athens University, Greece, Athens, Greece
Purpose: to evaluate the relationship between OPG and RANKL
in synovial ﬂuid and serum in patients with primary knee os-
teoarthritis and disease severity as it is graded radiologically
according to the system of Kallgren and Lawrence. To demon-
strate the role of the RANKL/OPG system in the pathophysiology
of primary knee osteoarthritis.
Methods: the study population included 37 patients (9 males,
28 females) with mean age 64.9 years (ranging from 50 to 80
years). Synovial ﬂuid was aspirated from the affected joint during
surgery where a total knee arthroplasty was performed. Blood
samples were obtained from the same patients 1 to 2 hours
before surgery. Anteroposterior weight bearing radiographs of
the patients’ knees were performed and osteoarthritic changes
were graded according to the system of Kallgren and Lawrence.
Results: we found that OPG concentration in synovial ﬂuid was
signiﬁcantly higher than in serum (257.5±76.9 vs 49.2±10.1
pmoles/lt, p<0,0001), indicating that the increase of OPG in
patients with knee OA is not systemic but rather localized in
the affected joint. OPG levels were increased in synovial ﬂuid
in relation with the severity of knee OA and were signiﬁcantly
higher in patients with OA grade 4 than in those with grade 1 or
2. RANKL levels were found low in both synovial ﬂuid and serum
(1.5±1.0 and 1.0±1.0 pmoles/lt respectively). Serum levels of
OPG and RANKL did not correlate with the severity of knee OA
Conclusions: based on the fact that OA is characterized by
progressive deterioration of the articular cartilage, the increase
of OPG in synovial ﬂuid of individuals with knee OA might
reﬂect a compensatory response by chondrocytes or synovial
ﬁbroblasts to destabilization of the coupling between degradation
and synthesis of articular cartilage. The increased concentration
of OPG might thus serve to protect cartilage rather than be a
cause of osteoarthritis.
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Purpose: Avocado and Soya (A/S 1:2 w/w) unsaponiﬁables
(ASU), developed and patented by Laboratoires Expanscience,
are the components of a medicinal product found in numerous
countries against degenerative osteoarthritis. The main ingredi-
ents are: 30% tocopherol, 25% sterols and 25% speciﬁc active
molecules. The originality is based on A/S ratio and Avocado
speciﬁc modiﬁed unsaponiﬁables obtained by chemical transfor-
mation of precursors. This modiﬁcation by hemisynthesis con-
stitutes one of the Laboratoires Expanscience know-how and is
patented.
In vitro published studies showed effects of ASU on the an-
abolism (increase in the synthesis of collagens, proteoglycans
and TGFβ) and catabolism (inhibition of synthesis of MMPs,
PGE2, and pro-inﬂammatory cytokines) of osteoarthritic chondro-
cytes. Moreover, clinical studies demonstrated the symptomatic
effect of ASU combined to a reduction in NSAID administration.
The pharmaceutical status requires perfect controls of the extrac-
tion process, of the hemisynthesis from precursors to converted
molecules and an excellent between-batch reproducibility.
This is ensured by a strict control of the whole plant process:
contractual partnerships with local subcontractors, expertise in
vegetable lipid chemistry allowing an exact deﬁnition of the plant
species extracted and the soils together with the application of
GMP rules for the whole process from the plant starting material
up to the pharmaceutical active ingredient.
Attracted by the scientiﬁc renown and success of pharmaceutical
ASU, nutraceutical companies have attempted to develop imita-
tions by suggesting more or less clearly a relation between the
composition and even the activity of the original pharmaceutical.
Methods: An analytical study of 7 nutraceutical products (for
human and veterinary uses) claiming the name ASU has been
performed by gas chromatography methodology.
Results: The analytical study of the nutraceutical products ver-
sus the original and authentic ASU showed:
– The complete absence of speciﬁc molecules which are
patented (obtained by transformation of avocado precursors)
evaluated by GC assay of silylderivatives on a 5%-phenyl-
methylpolysiloxane capillary column equipped with a cold on-
column injector and a FID detector;
– A content of unsaponiﬁables of less than 25% measured by a
method of the American Oil Chemistry Society N° Ca 6a-40;
– A lower sterol and tocopherol content of less than 15% and 5%
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respectively;- Presence of traces of other plant unsaponiﬁables
(like Colza unsaponiﬁables for example).
Conclusions: These nutraceutical products are therefore com-
pletely unrelated to the composition of the original pharmaceuti-
cal ASU. The quality of ASU is supported by a global know-how
concerning the qualitative management of the plant material from
it’s cultivation, extraction, hemisynthesis to it’s ﬁnal concentra-
tion. The original ASU alone may therefore claim a relationship
between the control of biodiversity, characterization of speciﬁc
structures and its pharmacological and clinical activity in os-
teoarthritis.
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Purpose: Cartilage biomarkers promise to advance our possi-
bilities to monitor articular cartilage damage and diseases by
non-invasive means. Complete medial meniscectomy has been
shown to lead to osteoarthritis(OA), in the human as in animal
models. In this study, complete medial meniscectomy was used
to investigate the potential of the collagenous biomarkers hydrox-
ylysylpyridinoline(HP) and lysylpyridinoline(LP) when measured
in urine.
Methods: New Zealand White rabbits (n = 32) had a complete
medial meniscectomy of their right knees using a medial parap-
atellar approach. Open surgery allowed a complete visualisation
of the joint structures at all timepoints of the procedure ensuring
a safe procedure. Postoperatively, the animals were housed in
cages. A group of 32 rabbits were used as unoperated controls.
8 rabbits of each group were sacriﬁced at 2, 4, 8 and 12 weeks.
Macroscopic mapping was performed on the right and left knee
joints using the scheme of the International Cartilage Repair
Society. Speciﬁc areas and sums of areas of all joint sites
were analysed for lesions. For microscopic evaluation, 4 µm
sections of the central tibial plateaus were stained with H&E
and Safranin O. Histologic analysis was performed with a ded-
icated grading system accounting for pathologic alterations of
proteoglycan content, matrix structure, cellularity, tidemark du-
plication, and osteophyte formation, basically a modiﬁed Mankin
scheme.
Urine samples were collected during the 24 hrs before surgery
and again during 24 hrs before each sacriﬁce time point. Mea-
surements of hydroxylysylpyridinoline (HP) and lysylpyridinoline
(LP) were performed with HPLC. Data were normalised to the
urinary creatinine. Ratios of the markers were calculated. Statis-
tical calculations were performed with SPSS using e.g. ANOVA,
Wilcoxon and Mann Whitney U tests.
Results: No signs of infection were noted during the postop-
erative course of the animals. Macroscopic lesions advanced
with time after meniscectomy. First degenerative changes were
already present at 2 weeks after surgery, with an increase in
number and size of lesions with time. Histologically, OA-like
lesions were present at all 4 examined timepoints.
The overall macroscopic, but not microscopic score correlated
inversely with the HP/creatinine ratio. The LP/creatinine ratio was
inversely correlated with either one.
Both HP/creatinine and LP/creatinine correlated inversely with
the overall histologic score. At the reported timepoints, both,
HP/creatinine and LP/creatinine ratios had generally lower mean
levels than the control animals. No simple timecourse which
might indicate a worsening osteoarthritic disease could be ob-
served with either ratio. This was also true for HP/LP.
Conclusions: Biomarkers have proven valuable in many bio-
logical systems and clinical situations eg in gastroenterology,
cardiology and oncology. Cartilage biomarkers are still under
development coming close to clinical utility. In this study, mea-
surements of HP and LP in the urine of rabbits after complete
medial meniscectomy did not show any simple signiﬁcant post-
operative changes. This was true for the respective ratios. Thus
we were not able to monitor the development of OA-like lesions
of the articular knee joint in a simple manner with these mark-
ers. Such somehow negative ﬁndings are part of a research
development which is still stimulating and will further our detailed
knowledge of cartilage and its diseases.
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URINE PRE-CLINICAL CTX II (CARTILAPS®) ASSAY
VALIDATION USING EQUINE URINE
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1University of Florida, Gainesville, FL; 2St. Lawrence College,
Kingston, ON, Canada
Purpose: The CTX II assay has been developed to examine
the type II collagen telopeptide that is released from articular
cartilage into the systemic circulation. In human osteoarthritis
(OA) patients, the Urine Cartilaps® ELISA has been reported
to be useful in the prediction of the progression of OA. Since
type II collagen is well conserved across species, this assay
was modiﬁed by the manufacturers into the pre-clinical assay to
allow for a broader measuring range of CTX-II concentrations in
non-human urine. Horses are one of the few species in which
adequate volumes of paired synovial ﬂuid, serum, and urine
samples can be collected and compared to allow correlation of
this marker in these different ﬂuids. This may lead to translational
beneﬁt to human OA patients. The purpose of this report was to
validate the use of the Urine Pre-Clinical CTX II assay for use
with equine urine for future use with equine models of OA.
Methods: Urine Pre-Clinical Cartilaps® ELISAs (Nordic Bio-
science Diagnostics) were used for this validation study ac-
cording to manufacturer protocols. Internal quality control (QC)
samples were prepared using the highest concentration standard
provided by the manufacturer (99 ng/ml). To create QC samples,
fresh urine was collected from 6 normal horses via catheteriza-
tion. The samples were pooled together for further processing
and analysis. Pooled samples were spiked with a known amount
of standard to create samples with high, medium and low levels
of CTX II. The QC samples were used to determine the pre-
cision, speciﬁcity, sensitivity, accuracy, linearity of dilution, and
stability of this assay with equine urine. To ensure that the assay
could detect different biological activity, 3 previously stored urine
samples from normal and OA horses were analyzed.
Results: Reproducibility of the standard curve was evaluated
(n=6 plates) by computing mean optical density (OD) and per-
cent coefﬁcient of variation (% CV) at each standard concen-
tration. The overall mean inter-assay CV of the standard OD
values was 6.5% (range 1.6-24.4%). Samples exhibited accept-
able intra-assay and inter-assay precision over 3 plates with an
overall mean CV of 4.3% (range; 1.2-12.3%) and 7.2% (range;
4.7-9.7%), respectively. Parallelism and linearity of dilution of
equine serum sample dilutions (1:2, 1:4, 1:8, and 1:10) were
demonstrated (Figure 1). Lowest detection limit of the assay was
determined to be 1.38 ng/ml. Percent recovery was 90% for high,
90% for medium, and 95% for low QC samples. There was no
loss in the stability of the CTX II epitope out to 4 freeze/thaw
cycles. Differences in biological activity were identiﬁed when ex-
amining 3 samples from normal (3.23 ± 0.38 ng/ml) and OA
(2.25 ± 0.37 ng/ml) horses (P=0.03) (Figure 2).
